Melts NAD+ Dissolving Strips

Graded D: no human data exist for NAD+ given by mouth, under the tongue or as a strip; NAD+ given by IV infusion is graded C.

Strengths: 30 strips (amount per strip not stated on the product page)
Also known as: Melts NAD+, Nicotinamide adenine dinucleotide strips
Contains: NAD+
Molecule: Coenzyme (not a peptide)
Mol. weight: 663 g/mol

Origin

A dissolving film containing NAD+, a coenzyme every cell uses for energy.

How it works

NAD+ is central to cellular energy metabolism, and its levels fall with age, which makes it a major aging-research topic. NAD+ is large and electrically charged, so crossing membranes is difficult, and anything swallowed passes through the gut. What reaches cells intact is unresolved even after IV infusion.

What the research shows

The main human NAD+ research uses IV infusion; no sublingual, buccal or oral NAD+ study was found. The NAD+ precursors with human oral data are different molecules: nicotinamide riboside (NR) raised blood NAD+ in randomized human studies, and NMN improved muscle insulin sensitivity in a small trial in women with prediabetes. Those results do not transfer to NAD+ itself.

Key studies

Grant et al., Frontiers in Aging Neuroscience 2019 IV NAD+ pilot; plasma NAD+ cleared rapidly and its breakdown products rose.
Trammell et al., Nature Communications 2016 Nicotinamide riboside is uniquely orally bioavailable in mice and humans and raised blood NAD+.
Yoshino et al., 2021 NMN improved muscle insulin sensitivity in 25 women with prediabetes.

Safety findings

Flushing, cramping and chest-pressure reactions linked to fast IV NAD+ are tied to infusion rate and may not apply to an oral film, but this form is unstudied. FDA has linked chills and vomiting after administration of NAD+ products to endotoxin from non-sterile-grade NAD+; this lot has no published purity or contaminant data. Excipients are unknown and there are no data in pregnancy, breastfeeding or children.

Regulatory status

There is no approved NAD+ drug. NAD is in FDA's 503A Category 1 for compounding (list dated May 14, 2026). In September 2025 FDA confirmed NMN as a lawful dietary supplement ingredient. NAD+ is not named on the 2026 WADA list.

Catalog notes

Offered as 30 strips; the product page does not state the amount per strip, while the October 15 wholesale listing gives 100 mg per strip. No certificate, product SDS or excipient list is published yet.